MDGL.NASDAQMadrigal Pharmaceuticals, INC

Form 4: Madrigal Director Sells Shares After Option Exercise

Sentiment:

Insider Transaction Report 7 November 2025 4:20 PM

📋All filings for Madrigal Pharmaceuticals, INC

Kenneth Bate, a Director at Madrigal Pharmaceuticals, Inc., exercised stock options and subsequently sold a significant number of common shares on November 5, 2025.

Worse than expectedA director sold a total of 16,575 shares of common stock, reducing their direct beneficial ownership. While this could be for personal financial planning, significant insider selling can sometimes be interpreted as a lack of confidence or a belief that the stock price is at a high point.

Summary

Kenneth Bate, a Director of Madrigal Pharmaceuticals, Inc. (MDGL), reported transactions on November 5, 2025.
He acquired a total of 16,575 shares of common stock through the exercise of stock options: 5,470 shares at $9.45, 10,000 shares at $303.79, and 1,105 shares at $280.04.
Immediately following the option exercises, he disposed of a total of 16,575 shares of common stock through multiple sales transactions.
The sales occurred at weighted average prices ranging from $480.2397 to $490.9817.
Following these transactions, Bate's direct beneficial ownership of common stock is 2,627 shares.
All underlying options were fully vested and exercisable prior to the transactions.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the insider selling a substantial number of shares after exercising options. While this is a common practice for diversification or tax planning, it still represents a reduction in direct insider ownership, which can be viewed cautiously by investors.

Positives

Director Kenneth Bate exercised stock options, indicating a prior belief in the company's value at the time of option grant.

Negatives

Director Kenneth Bate sold a significant number of shares (16,575 shares) after exercising options, which could be interpreted as a reduction in his direct equity exposure to the company.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders may interpret the director's sale of shares as a signal regarding the company's future prospects or current valuation, potentially influencing investor sentiment.

Key Dates

Date	Description
11/05/2025	Date of earliest transaction (stock option exercises and subsequent sales of common stock).
07/22/2026	Expiration date for 5,470 stock options with an exercise price of $9.45.
06/19/2028	Expiration date for 10,000 stock options with an exercise price of $303.79.
06/25/2031	Expiration date for 1,105 stock options with an exercise price of $280.04.
11/07/2025	Signature date of the reporting person's attorney-in-fact.

Recommendation

hold

The filing indicates a director exercised stock options and subsequently sold a significant number of shares. While this is a common practice for personal financial management, it represents a reduction in insider ownership. Without additional financial or operational context, this transaction alone suggests a 'hold' recommendation, as it introduces a cautious note but doesn't necessarily warrant a 'sell' given the lack of other negative company-specific news.

Keywords

Madrigal Pharmaceuticals, MDGL, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Director Transaction, Kenneth Bate

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.